SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentations at the Morgan Stanley Global Healthcare Conference and the UBS Global Life Sciences Conference. The live presentations will occur as follows:
Morgan Stanley Global Healthcare Conference 1:00 pm EST, September 13, 2011
UBS Global Life Sciences Conference 1:00 pm EST, September 20, 2011
To access the live presentations via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.
A replay of the Webcasts can be accessed for a minimum of one week and will be available approximately 24 hours after each live presentation.
XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant™ (gabapentin enacarbil) Extended-Release Tablets is XenoPort’s first FDA-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for gabapentin enacarbil in the United States. Gabapentin enacarbil is also being developed in partnership with Astellas Pharma Inc. for the potential treatment of restless legs syndrome in Japan. XenoPort’s pipeline of product candidates includes potential treatments for patients with neuropathic pain, spasticity and Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered U.S. trademark.
Jackie Cossmon, 408-616-7220
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Science Science